Congressional inquiry into 'highly atypical' FDA-Biogen ties ends with damning report, no repercussions
The FDA’s controversial approval of Biogen’s amyloid-targeted Alzheimer’s drug Aduhelm was “highly atypical” and “deviated” from FDA’s standard practices “in significant respects,” two key congressional …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
